We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genip Plc | LSE:GNIP | London | Ordinary Share | GB00BLCW2Q02 | ORD GBP0.00425 |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
23.00 | 25.00 | 24.00 | 24.00 | 24.00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
- |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
16:23:33 | O | 167 | 24.98 | GBX |
Date | Time | Source | Headline |
---|---|---|---|
22/10/2024 | 06:00 | UK RNS | GenIP PLC GenIP to Sponsor Technology Transfer Conference |
10/10/2024 | 06:00 | UK RNS | GenIP PLC GenIP recognises Nobel Prize in Physics |
08/10/2024 | 06:00 | UK RNS | GenIP PLC Corporate Update |
02/10/2024 | 09:10 | ALNC | TOP NEWS: Tekcapital investee GenIP starts trading on AIM |
02/10/2024 | 06:00 | UK RNS | GenIP PLC Admission to Trading on AIM-First Day of Dealings |
Genip (GNIP) Share Charts1 Year Genip Chart |
|
1 Month Genip Chart |
Intraday Genip Chart |
Date | Time | Title | Posts |
---|---|---|---|
30/10/2024 | 07:57 | GenIP Artificial Intelligence | 65 |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|---|---|---|---|
2024-11-05 16:23:34 | 24.98 | 167 | 41.72 | O |
2024-11-05 15:15:19 | 24.20 | 4,000 | 968.00 | O |
2024-11-05 13:52:55 | 24.20 | 2,461 | 595.56 | O |
2024-11-05 13:26:53 | 24.20 | 43 | 10.41 | O |
2024-11-05 11:22:32 | 24.98 | 20 | 5.00 | O |
Top Posts |
---|
Posted at 30/10/2024 07:57 by neilll77 🚀 TELEGRAM RUMOUR AFTER GenIP TWEET 🚀GenIP [GNIP] about to take off.. the share has been 'kept' under the radar!!!! Rumour of massive AI Health Care contract with a company in Singapore This follows from the below Tweet on X, "Building on deep relationships with leading research organisations, GenIP has been chosen as a preferred partner in Singapore. Further confirmation; once dignitaries, partners, clinicians, and key stakeholders in the healthcare ecosystem will conclude soon" SP nearly 50% below IPO but seller now out and that contract news imminent Big buys already landed today and share price is up 10% M/Cap only 3.3m and TEK [parent company] own over 66% of shares...so a very small "free float" When this moves it can do 15% with a few £1000 pound buys Plus really good news from another TEK 'off spin' SALT today will see much more interest around GenIP and TEK too hxxps://ukinvestorma GLA |
Posted at 15/10/2024 18:41 by jaknife WARNING WARNING WARNING WARNING!Several posters are posting unjustifiable positive spin on here trying to drive the share price up. |
Posted at 11/10/2024 20:17 by retirementfund WARNING WARNING WARNING WARNING!Several Posters are posting negative spin on here trying to drive down the share price. In my opinion |
Posted at 10/10/2024 20:22 by retirementfund WARNING WARNING WARNING WARNING WARNING WARNING WARNING!Several Posters are posting negative spin on here trying to drive down the share price. |
Posted at 10/10/2024 13:10 by abrahe00 Did they seriously just try to take credit for this? Or, suggest somehow that they are affiliated with it!!!?I'm sure those two scientists are thrilled that GenIP has "recognised" their achievement! |
Posted at 08/10/2024 12:17 by retirementfund WARNING WARNING WARNING WARNING WARNING WARNING WARNING WARNING WARNING WARNING!Several Posters are posting negative spin on here trying to drive down the share price. Below is what the company have said in their recent announcement:- 8 October 2024 GenIP Plc ("GenIP" or the "Company") Corporate Update GenIP plc, a technology business providing Generative Artificial Intelligence (GenAI) services to help research organisations and corporations commercialise their innovations, is pleased to provide an update on orders for the GenAI enhanced services since their launch on 1 September 2024. Highlights: · Since launching GenAI services, orders worth approximately $121,000 have been secured, representing over 40% of legacy service full-year 2023 revenue · This includes over 80 Invention Evaluator Generative AI analytical assessments · Winning four Vortechs executive search assignments · Leading Fortune 500 technology company client has doubled the pace of orders after GenAI enhancements · Advanced discussions with multiple research organisations over new orders · GenIP has been Invited to attend leading international technology transfer events by long-term partners The volume of initial orders is very encouraging and the Company anticipates the level of new orders from current and new customers to grow. Invention Evaluator Invention Evaluator's Generative AI algorithms are now fully integrated and are generating enhanced analytical commercialisation assessments for our clients at a high efficiency level. Since the beginning of September 2024, new and existing clients have placed over 80 fresh orders for Invention Evaluator Generative AI analytical assessments. Vortechs Vortechs' advanced machine learning and natural language processing executive search services has received several new assignments in the technology transfer sector. GenIP's sales team is engaged in advanced negotiations with multiple research organisations representing a robust Vortechs pipeline of new business. International Technology Transfer Event Participation Building on deep relationships with leading research organisations, GenIP has been invited to attend a significant healthcare event in Singapore, where dignitaries, partners, clinicians, and key stakeholders in the healthcare ecosystem will gather. In addition, GenIP will address delegates at a major technology transfer event in Brazil. This event will bring together over 500 qualified attendees, including representatives from more than 60 Technology Transfer Offices (TTOs) across Brazilian universities and research centres. GenIP looks forward to providing further updates on commercial progress in due course. The Company does not plan to provide monthly updates on sales or orders and will provide updates on material developments. Melissa Cruz, CEO of GenIP, comments: "We are highly encouraged by the strong demand for GenIP's Generative AI analytic services over the past five weeks, with total orders amounting to approximately $121,000. We remain laser-focused on building on this momentum, expanding our client base, and delivering our services to research organisations globally." In my opinion |
Posted at 07/10/2024 12:53 by neilll77 I have sent this email to investor relations and will post their reply, if I receive 1.Good afternoon, I think we need an via update of trading and the plans for the immediate future, as the share price is crashing. Also you may want to question LSE why the share price drops on £250 sells , but buys upto and over £6000 are not moving the share price At 25.30p it is now over 40% down from IPO price!! As an investor in GenIP, I'm very frustrated and disappointed Regards and I'd really appreciate a reply |
Posted at 07/10/2024 05:17 by neilll77 IPO Price: 39pSP Now: 27p Free Float: 24.48% Number of Ordinary Shares in issue: 17,517,461 Market Cap: £4.7 Millon Main points from the above figures IMHO are; ☆SP down 30% since IPO ☆M/CAP Less than 5 Million and they are ALREADY generating circa "1 Million per annum" and the CEO expects those to increase greatly and quickly ☆Less than 25% Free float ☆Remember; SALT did nearly 200% above their IPO in the first 3 months of trading on LSE I expect positive updates this next 5/7 days, as SALT did regularly after their IPO, and GENIP moving back to, or above the 39p IPO. Best of luck holders 👍 |
Posted at 06/10/2024 10:29 by neilll77 hxxps://audioboom.coInterview attached again but maybe deleted by ADVFN |
Posted at 02/10/2024 14:21 by backmarker It may be because you can't buy them.I tried to get a quote on ii but it did not find GNIP. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions